STARD3

Across TCGA pan-cancer cohorts, STARD3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated STARD3 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher STARD3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated STARD3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

GBM, PDAC, and LUAD are the cancer types where STARD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.266	0.654	<.001	30	view →
PDAC	OS	Median	All	0.355	0.589	.002	29	view →
LUAD	OS	Median	All	0.746	0.971	.007	15	view →
LSCC	OS	Median	III,IV	1.000	0.740	.009	8	view →
HNSC	DFS	Quartile	III,IV	0.737	1.000	.036	2	view →
UCEC	DFS	Median	All	0.855	0.949	.019	2	view →
CCRCC	DFS	Median	All	0.765	1.000	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

STARD3–GBM (OS)

Open the GBM breakdown →